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ABSTRACT
The ‘RandomMutation Capture’ assay allows for the
sensitive quantitation of DNA mutations at extreme-
ly low mutation frequencies. This method is based
on PCR detection of mutations that render the
mutated target sequence resistant to restriction
enzyme digestion. The original protocol prescribes
an end-point dilution to about 0.1 mutant DNA mol-
ecules per PCR well, such that the mutation burden
can be simply calculated by counting the number of
amplified PCR wells. However, the statistical
aspects associated with the single molecular
nature of this protocol and several other molecular
approaches relying on binary (on/off) output can sig-
nificantly affect the quantification accuracy, and this
issue has so far been ignored. The present work
proposes a design of experiment (DoE) using statis-
tical modeling and Monte Carlo simulations to
obtain a statistically optimal sampling protocol,
one that minimizes the coefficient of variance in
the measurement estimates. Here, the DoE
prescribed a dilution factor at about 1.6 mutant mol-
ecules per well. Theoretical results and experimen-
tal validation revealed an up to 10-fold improvement
in the information obtained per PCR well, i.e. the
optimal protocol achieves the same coefficient of
variation using one-tenth the number of wells used
in the original assay. Additionally, this optimization
equally applies to any method that relies on binary
detection of a small number of templates.
INTRODUCTION
Mutations in nuclear and mitochondrial DNA are
associated with congenital disorders, diseases (e.g.
cancer) and ageing (1). An accurate determination of
tissue level DNA mutation abundance is challenging, but
critical for understanding the impact of these mutations
on cellular and tissue physiology (2–4). Furthermore, the
ability to sensitively detect the frequency of random spon-
taneous mutations of DNA is necessary to deﬁne critical
parameters like the mutation rate, which is essential for
understanding the role of genomic mutagenesis in human
diseases and ageing.
Many procedures have been developed based on quan-
tiﬁcation of point mutation frequency by PCR ampliﬁca-
tion of short fragments of DNA. However these methods
have recently come under criticism, because
mis-incorporation of nucleotides due to the intrinsic
error rate of polymerase enzymes will result in introduc-
tion of spurious mutations during the initial PCR step.
Upon cloning, these mutations become indistinguishable
from true mutations and may provide an overestimation
of the mutation load (5). These artifactual mutations may
be at frequencies exceeding actual in vivo mutation
frequencies, especially when measuring low-level spontan-
eous DNA mutations (106bp1) (6).
In 2005, Bielas and Loeb (3) developed a novel assay for
quantifying low levels of spontaneous random mutations
in DNA. This method, known as the ‘Random Mutation
Capture’ (RMC) assay, is based on PCR detection of
mutations that render the target sequence resistant to
restriction enzyme digestion (2,4). Following complete
restriction digest, digest resistant mutant templates are
quantiﬁed by real-time PCR ampliﬁcation after dilution
to single molecule level (5). This approach avoids the
need for pre-ampliﬁcation and associated artifactual mu-
tations due to polymerase error that have confounded
previous methods (2).
Given these advantages, it is not surprising that the
RMC assay has been widely applied. Since it was ﬁrst
described in 2005 (3), 17 studies reporting original data
based on the RMC method have been published. Data
based on the RMC assay has also been central to some
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very high impact results. For example, RMC data on the
point mutation and deletion burden in the mtDNA of
polymerase gamma ‘mutator mice’ has been cited over
190 times (7,8). Also, application of the RMC assay to
the determination of the mutation frequency in mitochon-
drial DNA (mtDNA) of ageing wild-type mice (7) has
resulted in values about two orders of magnitude lower
than the previous estimates (9,10), a result that has wide
reaching implication in the context of ageing (11). The
RMC assay itself has been widely discussed, with over
21 additional articles and reviews discussing it (see
Supplementary Table S2).
The RMC assay is based on quantiﬁcation of mutation
burdens by real-time PCR following dilution to single
molecule level (Figure 1). The advantage of this
approach is that each PCR-ampliﬁed well results from
only single mutant molecules because the likelihood of
ﬁnding more than a single mutant in a well is negligible
(3,5). However, while at the population level, low sample
size has been shown to negatively affect the conclusion
drawn from DNA mutation studies (12), here we show
that statistical aspects related to protocols necessitating
such high dilution (down to single molecule level) can
also introduce signiﬁcant noise in the mutation frequency
estimates. Unfortunately, the statistics associated with the
discrete molecular nature of such assays can become
non-trivial, an aspect that was overlooked in the original
protocol and subsequent applications. In this work, a
novel optimization of the RMC assay has been developed
based on statistical modeling techniques. These statistical
techniques are used to investigate the impact of high
dilution endpoints in the RMC assay on the accuracy of
mutation frequency measurements.
The statistically optimized RMC assay developed in this
work not only signiﬁcantly reduces the extent of measure-
ment variability, facilitating better hypothesis testing, but
also increases the amount of information returned per
sample. Additionally, most PCR assays involving single
molecular dilution protocol, other than the RMC assay,
such as the digital PCR (dPCR) (13–15) or digital
RT-PCR (16) and single molecular PCR (smPCR)
(6,17,18), utilize a DNA template dilution factor of
50% (one in two wells amplifying). The selection of
this dilution factor is chosen to yield ‘single’ DNA
template per PCR well and with the intention of
maximizing information return per well by assuming
Binomial statistics. However, the analysis in this work
demonstrates that this end-point dilution, while better
than the higher dilution of the RMC assay, may also be
suboptimal with respect to measurement variability. A
more careful and rigorous mathematical analysis, such
as the one presented here, will therefore not only beneﬁt
the RMC assay but may also be equally applicable to
other single molecule assays.
METHODS
Statistical optimization of the RMC assay
The conventional RMC assay (3,5,7) is based on PCR
ampliﬁcation of a single mutant molecule (restriction
enzyme digest resistant) in the presence of excess copy
numbers of wild-type sequences (digest sensitive). The
mutation frequency is calculated by dividing the fraction
of PCR wells that are ampliﬁed by the amount of DNA
per well (3,7). In the conventional RMC assay, intrinsic
variability arises due to the well-to-well and plate-to-plate
variability that can arise from non-uniform sampling
of DNA content to PCR wells at single molecule level
dilutions and from the random number of ampliﬁed/
non-ampliﬁed wells in a plate, respectively (Figure 1).
The other sources of error (bias) in this protocol are
associated with (i) the assumption that each ampliﬁed
well only contains a single mutant molecule, (ii) false
Type of
uncertainties
Homogenized
DNA buffer
Typical RMC assay
Inter-plate variability
(Binomial-
 distribution)
Inter-well variability
(Poisson-
distribution)
type - I errors
(false-amplification)
type - II errors
(mis-
amplification)
Figure 1. Statistical aspects associated with the RMC assay. There are primarily four sources of variability that are important for the sensi-
tive estimation of DNA mutation load using the RMC assay, including: (i) the number of PCR (un)ampliﬁed wells among independent
RMC trials (inter-plate variability) even when each PCR well receives same number of DNA templates, (ii) the random molecular count of
mutant DNA in different wells of a single plate (inter-well variability), (iii) false ampliﬁcation (Type I error) and (iv) mis-ampliﬁcation (Type II
errors).
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PCR ampliﬁcation due to contamination or incomplete
digestion (Type I), and (iii) failed PCR ampliﬁcation
(Type II). Each of these factors contributes in a non-trivial
manner to the statistics of the mutation frequency data,
and has not been addressed previously.
To arrive at the optimal protocol, two types of
statistical analyses were performed. The ﬁrst involved a
linearized variance propagation of functions of random
variables arising from the variability due to the
non-uniform sampling of DNA content to PCR wells,
while the second used a Monte Carlo approach involving
the function of random variables, that simulates the
protocol a large number of times (n=10000). The opti-
mization was then performed to minimize the coefﬁcient
of variation, by changing the amount of DNA molecules
that were sampled into each well. The details of each
analysis are outlined below.
First order uncertainty propagation analysis
Assuming that the DNA homogenate for which mutation
frequency is to be determined is well mixed, the probabil-
ity of sampling x number of mutant molecules into a PCR
well, which is associated with the well-to-well variability,
can be described by the Poisson distribution with a mean
of l. This mean is the quantity of interest in this assay as
the point mutation frequency (per bp) can be calculated by
dividing l with the total amount of DNA in a well. Using
the Poisson density function, the probability of sampling
zero mutant template into an PCR well, denoted by p0, is
given by:
p0 ¼ PPoisson x ¼ 0ð Þ ¼ el ð1Þ
Furthermore, assuming that p0 is constant and ignoring
the Type I and II errors described earlier, the number of
wells n0 that are not PCR-ampliﬁed among a total of nwells
wells is an outcome of Bernoulli trials, similar to coin
ﬂipping. While the number of unampliﬁed wells (n0) has
an expectation value of nwells p0, the outcome from a
particular RMC assay follows a random Binomial distri-
bution, giving rise to the plate-to-plate variability. In
this case, we can only obtain an estimate of p0, which is
calculated as p^0 ¼ n0=nwells: Here, we show that the quality
of estimating l depends in non-trivial ways on p0.
An estimate of l can be calculated from p^0 by
rearranging Equation (1), such that:
l^ ¼  log p^0 ð2Þ
Since p^0 is an unbiased estimator of p0 (i.e. the expected
value of p^0 is equal to p0), the variance of l^ can
approximated by using a Taylor series expansion of
Equation (2) and the coefﬁcient of variation (CV) of l^
is given by (see Supplementary Data for a detailed
derivation):
CV l^
 

ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃð1 p0Þ=ðnwellsp0Þ
p
 logðp0Þ : ð3Þ
Using the above function, the minimum CV is attained at
p0 ¼ 0:20: That is, the optimal (smallest) CV results from
choosing a template dilution where 80% of wells amplify.
Note that the mutation burden here is computed from the
fraction of PCR wells that are not ampliﬁed, as opposed
to counting wells that are PCR-ampliﬁed in the conven-
tional RMC assay and other types of single molecular
dilution assays. However, a similar optimization based
on the fraction of ampliﬁed wells gave the same optimal
sampling protocol.
Our analysis shows that all methods involving single
molecule protocol relying on binary reading (e.g.
ampliﬁed or not ampliﬁed), such as the RMC assay,
dPCR and smPCR, are fundamentally quite different
from traditional biochemical assays. In particular we
ﬁnd that their statistical properties are not trivial. What
the optimal protocol, e.g. in terms of information-
return-per-well and robustness with respect to errors,
should be is not obvious without a thorough statistical
analysis, such as one carried out in this article. It is intui-
tively clear that the ideal percentage of ampliﬁed wells
should lie somewhere between zero ampliﬁed wells
(no information gained) and 100% of wells ampliﬁed
(also no information gained). One could further argue
that counting the number of non-ampliﬁed wells is equiva-
lent to counting the number of ampliﬁed wells (since both
arise from the same Bernoulli trials), and it might there-
fore be expected that the maximum information per well
should correspond straightforwardly to the points when
half of the wells are ampliﬁed (or not ampliﬁed). However,
a further careful and detailed analysis shows that this is
not the case. The reason for this lies in the Poissonian
random sampling of DNA templates into the PCR
wells. This leads to l^ being a logarithmic function of p0
[Equation (2)]. The logarithmic function is signiﬁcantly
non-linear near 0 and hence, any small differences in the
measured p^0 near 0 will be disproportionately magniﬁed in
the l^ estimates (Figure 2A). Consequently, the SD of l^
increases dramatically at high dilution [see the numerator
of Equation (3)]. On the other hand, increasing the
average number of ampliﬁable templates per well
beyond the optimal level comes with a diminishing
return in reducing the CV of l^. In this case, the beneﬁt
of reducing variance by increasing p0 is counterbalanced
by the corresponding decrease in the mean of l^. This
tradeoff thus explains the skewed optimal point for CV
at p0 ¼ 0:20:
Monte Carlo analysis
The analytical treatment discussed earlier does not
consider false positives and false negatives (Type I or
Type II errors) as described in Figure 1. To better under-
stand the inﬂuence of these errors on the mutation fre-
quency estimates, we have also performed Monte Carlo
(MC) simulations of the conventional RMC assay and the
proposed alternative protocol (i.e. counting non-ampliﬁed
PCR wells) with and without these errors. When PCR
ampliﬁed wells contain exactly 1 mutant molecule,
sequencing of the PCR product can eliminate false posi-
tives and at the same time provide the mutational spectra.
Using a high dilution factor, the conventional RMC assay
assures that most, if not all, of the wells contain 0 or 1
mutant molecule and in this case, Type I error can be
PAGE 3 OF 9 Nucleic Acids Research, 2012, Vol. 40, No. 5 e35
made negligible by sequencing. Consequently, the Type I
error rate was set to zero in the MC simulations of the
original RMC protocol. In the case of the proposed
optimized RMC assay, since some PCR wells have more
than a single DNA template, the likelihood of ﬁnding
more than a single type of allele is higher compared to
the conventional RMC assay. Also, each PCR ampliﬁed
wells of the optimized assay would, on an average, contain
two DNA templates (for p0 ¼ 0:20). While this does not
preclude the usage of sequencing or other more advanced
technologies to exclude Type I errors in the case of
proposed optimal RMC assay, it does make these
controls slightly more challenging. Thus, for the MC
simulations of the optimized assay, we have considered
both the Type I and Type II errors. Type I and Type II
error frequencies for the MC simulations were estimated
from experimental data (see Supplementary Table S1).
It should further be noted that setting Type I errors to
zero in the simulations of the traditional but not the
optimized RMC assay is conservative (favoring the trad-
itional RMC assay).
Each MC simulation emulated the statistical random
sampling of DNA material into each PCR well on a
plate and the PCR ampliﬁcation experiment. In this
case, such a simulation was performed a large number
of times to obtain the statistics of the mutation frequency
estimates, such as the mean and CV. The pseudo-codes
for the MC algorithms are given in Supplementary
Data. The Monte Carlo algorithms were implemented in
C++on a Linux Platform [CentOS; GNU C++compiler
(v4.1.1)] using a combination of a long period random
number generator (19) and a multiple independent
streams generator (20). In addition, non-uniform
random numbers were generated using algorithms
described elsewhere (21,22). The codes will be made avail-
able upon request.
Validation of RMC optimization
The performance of the proposed optimized protocol was
compared against experimental data from a mock RMC
assay to validate theoretical and simulation predictions.
Brieﬂy, we generated a plasmid containing the target
sequence and a matching TaqMan probe/primer set
based on the TaqMan MGB Probe with 50-6FAM and
30-MGBNFQ dye technology (Applied Biosystems,
Calif.). The plasmids were serially diluted to approximate-
ly either 0.1 or 1.6 molecules per microliter. The former
corresponds to the dilution used in the single molecule
ampliﬁcation of the original RMC assay (3), while the
latter represents the suggested dilution of the optimized
assay ðl^ ¼  log p^0 ¼ 1:6Þ. A 1-ml sample of either the
high or the low copy number dilutions were added to a
19 ml of standard TaqMan UDP master-mix (TaqMan
Universal PCR Master Mix, Applied Biosystems, CA,
USA) to each well of a 96-well plate PCR plate (Applied
Biosystems). The wells were subsequently subjected to
PCR ampliﬁcation and detected using an Applied
Biosystems 7500 real-time PCR system running 60 cycles
of PCR of a modiﬁed universal ampliﬁcation proﬁle (50C
for 2min, 95C for 10min followed by 60 cycles of: 95C
for 45 s, 55C for 45 s and 72C for 90 s). Ampliﬁcation
was monitored at 520 nm (FAM Dye) and under these
conditions single molecules are found to be reliably
ampliﬁed (data not shown).
Conceptually, the RMC assay comprises two stages.
During the ﬁrst stage WT DNA templates are removed
with high efﬁciency by complete restriction digest, leaving
only low copy numbers mutant templates. In the second
stage (‘quantiﬁcation stage’), these mutant templates are
A
B
Figure 2. Optimized RMC assay. (A) Coefﬁcient of variation (CV) of
DNA mutant frequency as a function of p0 (the mean fraction of un-
ampliﬁed wells) as predicted by MC simulations and statistical analysis
using assay with 48 wells. The parameter p0 relates to the DNA
template dilution factor, where higher dilution increases p0 (fewer
DNA templates per PCR well). The CV has a minimum value
around p0=0.20, as opposed to the conventional RMC assay of
p0& 0.91. The lower CV in simulations with Type I and Type II
errors comes at the cost of lower accuracy due to bias. (B)
Comparison of the relative errors between optimized and conventional
RMC assays in (X and Y) simulation and (Z) experiment; (nwells=48,
see also Table 1). MC simulations (n=10000 realizations) were per-
formed (X) with and (Y) without Types I and II errors. The Types I
and II errors were determined based mock RMC repeats (n=100 PCR
wells, Supplementary Table S1). For the original RMC assay, Type II
error rate was the same as above, but Type 1 frequency was set to zero,
since existence of mutant DNA in ampliﬁed wells is conﬁrmed by
sequencing. Both MC simulations and experimental data conﬁrmed
the superiority of the optimized protocol in terms of CV reduction
and accuracy improvement.
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further diluted to single molecule level (limiting dilution)
and quantiﬁed using the discrete RT-PCR step (only in-
formation regarding ampliﬁcation or no ampliﬁcation is
used). The ﬁrst ‘digest’ stage of the RMC protocol
involves methodological challenges of its own, including
digestion efﬁciency of restriction enzymes, star activity
and template degradation. However, these will vary
from one application to another and can be minimized
without the use of a rigorous statistical analysis. Our
analysis is concerned purely with the second stage, in par-
ticular with the effect of randomness and sampling due to
the single molecule sampling step. Much of the aspects in
the quantiﬁcation stage of the assay can be captured by
preparing limiting dilution series using plasmids contain-
ing the mutant sequence. In terms of validation of our
modeling claim, the use of plasmids is preferable because
the copy number of plasmids can be very accurately
determined beforehand and identical samples can be
generated each time. The use of whole genome samples,
while possible, would signiﬁcantly complicate the protocol
without adding additional insight into the question
explored here. In practice, the use of higher mutant tem-
plates per well, as suggested by the optimization, will con-
comitantly increase competing WT DNA copies, which
may possibly affect single molecule detection efﬁcacy.
Detection limit should therefore be validated using appro-
priate control experiments such as spiking pre-digested
WT samples with mutant or uncut WT DNA at known
copy number. Such control should in any case be a part of
assay calibration together with controls to ensure that
only WT sequences are cut during restriction digestion.
RESULTS AND DISCUSSION
Following the derivation in the Method section, the
optimal protocol involves (i) preparation of DNA
sample such that about 1 p0 fraction of the wells will
be ampliﬁed by adjusting the dilution factor and (ii) the
mutation frequency estimate ^ (mutations per base pairs)
can be computed according to
^ ¼ l^
nbpnDNA
ð4Þ
where nDNA is the total number of DNA molecules in
a single PCR well and nbp is the length restriction site
[nbp=4 for TaqI recognition site (7)]. Figure 2 shows
that the results of statistical optimization using the
linearized analysis and MC approach, and from the
RMC validation experiments. In particular, Figure 2A
and Supplementary Figure S1 suggests that the
minimum CV can be achieved by diluting DNA sample
such that 1 p0 ¼ 80% of the wells are PCR ampliﬁed,
which corresponds to 1.6 mutant molecules per well. This
is in contrast to the original RMC assay that prescribes
end-point dilution down to 0.1 mutant molecules per well.
Importantly, the optimized protocol offers a signiﬁcant
improvement of the accuracy in mutation estimates
compared to the conventional RMC assay. For example,
Monte Carlo (MC) simulations of RMC assays
(n=10000) on 48 PCR wells (nwells=48) predicted a
53% reduction in coefﬁcient of variation (CV) (from
40% to 19% CV) by using the optimal protocol in place
of the original (Figure 2B). Furthermore, this protocol
provides a more robust estimate of  than the traditional
RMC assay, where the CV is approximately constant for
the values of p0 between 0.1 and 0.4, even in the presence
of experimental artifacts (false positive and false negative
errors) (Figure 2A, Supplementary Figure S1). Even at
much higher false ampliﬁcation and non-ampliﬁcation
errors (Type I and Type II errors up to 30%), the
optimized protocol could still provide a signiﬁcant reduc-
tion in the CV and better overall accuracy of mutation
burden estimates over the conventional RMC assay
(Supplementary Figures S2 and S3).
We tested the theoretical predictions experimentally by
conducting a mock RMC assay using plasmid DNA (see
Method). As expected, at the optimal dilution factor of
p0 ¼ 0:20, this protocol provides a substantial reduction
of variability with an actual CV reduction of 68% (from
57% to 18% CV) (Figure 2B and Table 1). In other words,
the optimal RMC protocol offers the same information as
the original protocol using only 1/10 the number of wells
and provides signiﬁcantly higher accuracy. The high vari-
ability due to the discrete molecular nature of the original
assay can lead to a signiﬁcant uncertainty in measurement
estimates. These ﬁndings highlighted that in the quanti-
ﬁcation of low-level DNA mutations, the manner in
which samples are prepared for analysis can contribute
non-trivially to the statistics of the measurement data.
Given the increasing utilization of the RMC and similar
limiting dilution assays (8,17), we feel that this insight is
important to maximize information and minimize meas-
urement uncertainty when using these types of assays.
At p0 ¼ 0:20 a great majority (>98%) of the ampliﬁed
wells still contain at most four DNA templates. Although
the conventional sequencing techniques are best applied to
only single DNA template, the sequencing of up to four
mutant molecules in a single well of the RMC assay
should not pose much difﬁculty, especially considering
that different templates are present at high and ap-
proximately equal number post-PCR ampliﬁcation.
In addition, as the typical applications of RMC assay
involve point mutation frequencies of 106–104bp1,
the probability of having multiple mutations in a single
4-bp restriction site is negligible. Thus, by assuming that
each mutant molecule contains only a single point
mutation, the sequence of each DNA template in the
PCR well can be uniquely and straightforwardly identiﬁed
from multiple chromatogram traces in the sequencing
output (23). Alternatively, if more accuracy is required,
a clone and sequence approach can be followed (23).
Finally, more advanced RT-PCR techniques for allelic
discrimination exist that can be used to conﬁrm if any
WT alleles are present in the wells (24).
Additionally, it should be noted that the CV is not a
strong function of the fraction of ampliﬁed wells between
30% to 80% positives (0.2 p0 0.7, see Figure 2A).
Using a value of p0 in this range, it is possible to obtain
improved accuracy of the mutation burden, while
resolving the complexity of DNA sequencing, if this is
desirable. For instance, at a dilution giving 30% ampliﬁed
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wells (0.35 molecules per well, p0=0.7), a great majority
of ampliﬁed wells (four out of ﬁve) will contain only a
single DNA template per well and 99% of ampliﬁed
wells contain at most two DNA templates. While the cor-
responding CV is suboptimal, this level of dilution can still
provide 50% reduction in CV from the conventional
RMC assay and also make sequencing easier (see Figure
2A). Therefore, if determining mutation spectra is of a
major interest, an intermediate dilution factor can be
chosen and Figure 2A can be used to estimate the trade
off in information loss.
Applications of the RMC assay in the past have been
for quantifying DNA mutation burden in numerous cell
types and in different organisms (see Supplementary Table
S2). A majority of these applications has been concerned
with age-dependent mutation burden in mitochondrial
DNA. Most of these applications have been used predom-
inantly in the original form. While a modiﬁcation of the
RMC assay was recently proposed (25), the modiﬁed
protocol still used the original DNA dilution and
sampling procedure and did not address the issues high-
lighted earlier. Experimental data in the proposed work
(25) shows that their modiﬁed RMC assay using the same
DNA homogenates still exhibited high degree of noise
with half of the repeats having >50% differences and a
quarter have >100% deviations [see Figure 5 in (25)]. As
the measurement of each DNA homogenate was only
repeated once, it is statistically difﬁcult to conclude
further about the reproducibility of their modiﬁed assay.
To elucidate the impact of the optimal protocol developed
in this work in reducing the measurement noise and
further improving the quality of data on age-dependent
mtDNA mutation accumulation, we have further per-
formed Monte Carlo simulations of low-level accumula-
tion of mtDNA mutations during ageing and their
measurements using the RMC assay with the original
and the optimal protocol.
Brieﬂy, based on our earlier work (26), the in silico
mouse model tracks for the accumulation of mtDNA
point mutations during two stages of mouse life: develop-
ment and post-development. The model simulates two
mtDNA-related maintenance processes: mitochondrial
turnover, comprising of relaxed replication and
degradation of mitochondrial DNA, and de novo point
mutation during the mtDNA replication. In development,
the replication of the mtDNA during the symmetric
binary cell divisions is simulated, starting with a single
progenitor cell. In the post-natal stage, however, relaxed
replication of the mtDNA in a post-mitotic cardiomyocyte
is simulated (more details are included in Supplementary
Data).
Figure 3A shows the intrinsic variability in the levels of
mtDNA mutations among heart tissues from a population
of mice that may arise from random drift of mtDNA
point mutations. The underlying density function of this
uncertainty is represented as g(y) where y is the mtDNA
mutation frequency. The variability of RMC mutation
burden data in this population is a combination of the
intrinsic variability above and the uncertainty associated
with the RMC assay protocol (original and optimized),
which can be calculated by:
hðmÞ ¼
X
g ð Þ 	 f mjð Þ ð5Þ
where f(m|y) is the probability of obtaining a mutation
burden reading of m by RMC assay, when the true
mutation frequency is y (26, 27). When using the
original RMC assay, the additional variability (noise)
from suboptimal sampling of the original RMC assay pre-
vents any deﬁnitive conclusion regarding the dynamics of
mtDNA mutation accumulation, as shown in Figure 3B.
On the other hand, the reduction in the sampling variabil-
ity offered by the optimal protocol provides a much more
deﬁnitive insight into the mutation dynamics (Figure 3C),
which is important in deducing mechanisms of age-related
mtDNA mutations (26).
CONCLUSIONS
Methods for quantifying extremely low levels of mutation
frequency (106bp1), like the RMC assay (3), represent
an important technological advance. Our ﬁndings reveal
that the statistics associated with the sample preparation
in these assays are of great importance, but often over-
looked. Consequently, sampling protocols need to be care-
fully designed to maximize signal-to-noise ratio. Here we
Table 1. Mock RMC experimental results using the optimized and original protocol
Optimized protocol (=1.6) Original protocol (=0.1)
Fraction of
ampliﬁed wells
ð1 p^0Þ
Average mutant
molecules per well
 ¼  logðp^0Þ
Fraction of
ampliﬁed wells
ð1 p^0Þ
Average mutant
molecules per well
ð ¼ 1 p^0Þ
Run # 1 36/48 1.39 Run # 1 1/48 0.02
Run # 2 39/48 1.67 Run # 2 6/48 0.13
Run # 3 38/48 1.57 Run # 3 10/48 0.23
Run # 4 35/48 1.31 Run # 4 7/48 0.16
Run # 5 36/48 1.39 Run # 5 6/48 0.13
Run # 6 42/48 2.08 Run # 6 3/48 0.06
Average (molecule per well) 1.5668 Average (molecule per well) 0.1146
SD (molecule per well) 0.2854 SD (molecule per well) 0.0656
CV 0.1822 CV 0.5721
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show that a sensitive and more robust estimate of
mutation frequency can be obtained by a simple modiﬁ-
cation of the original assays (3,5,7) based on statistical
analysis. While the original procedure prescribes a
dilution factor of about 0.1 molecules of mutant per well
and the counting of ampliﬁed wells, we found, however,
that the maximum signal-to-noise ratio corresponds to a
lesser dilution factor of 1.6 molecules per well and quan-
tifying the fraction of unampliﬁed wells. The optimized
assay is predicted and conﬁrmed by experimental data,
to substantially reduce the measurement variability, and
thus provide signiﬁcantly more accurate estimates of
mutation frequency, for instance in age-dependent
mutation dynamics. While the work developed here
pertains to the RMC assay, the statistics related to
sample preparation and sampling protocol maybe more
generally applicable to other DNA quantiﬁcation tech-
niques requiring high dilution to obtain single molecule
end point dilutions.
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